Last reviewed · How we verify
Fluzone® standard IIV3
Fluzone® standard IIV3 is a Biologic drug developed by Stanford University. It is currently FDA-approved.
At a glance
| Generic name | Fluzone® standard IIV3 |
|---|---|
| Sponsor | Stanford University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone® standard IIV3 CI brief — competitive landscape report
- Fluzone® standard IIV3 updates RSS · CI watch RSS
- Stanford University portfolio CI
Frequently asked questions about Fluzone® standard IIV3
What is Fluzone® standard IIV3?
Fluzone® standard IIV3 is a Biologic drug developed by Stanford University.
Who makes Fluzone® standard IIV3?
Fluzone® standard IIV3 is developed and marketed by Stanford University (see full Stanford University pipeline at /company/stanford-university).
What development phase is Fluzone® standard IIV3 in?
Fluzone® standard IIV3 is FDA-approved (marketed).
Related
- Manufacturer: Stanford University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing